Corporate capital at Series A brings credibility and distribution, and can narrow your buyer pool later. Conduct's record shows a $60M Series A with a corporate alongside venture leads. Keep the corporate a minority participant with no special rights.
Key takeaways
- Take corporate capital alongside a venture lead, never as the lead, at early stages.
- Refuse rights of first refusal and exclusivity — they reduce your future buyer pool.
- Convert distribution promises into named pilots with owners and dates before signing.
A large software company on your Series A cap table is an endorsement your sales team can use on the first call. It can also quietly reduce the number of companies willing to buy you later. Both are true, and the difference is in the terms.
The documented case here is Janphilipp Haas, founder of Conduct (London, United Kingdom).
| | | |---|---| | Founder | Janphilipp Haas | | Company | Conduct (London, United Kingdom) | | Total raised | $72M | | Latest round | Series A — $60M | | Round date | June 2026 | | Named participants on record | Index Ventures, ICONIQ, SAP, Creandum |
Two venture leads, one growth investor and one corporate — the corporate is a participant, not the lead. That ordering is the point.
Category credibility with enterprise buyers who care who else believes you.
Integration proximity, if your product sits in their ecosystem.
Distribution, in theory. In practice, only if named people commit to named pilots.
Rights of first refusal or first offer on an acquisition. This is the single most damaging term. It tells every other potential acquirer that their bid is a free valuation exercise for your investor.
A board seat at Series A. Observer rights are the maximum, and even those need care where competitive information is involved.
Information rights over roadmap beyond standard financial reporting.
Written into the round documents or a side letter: which teams, which quarter, which named executive sponsors, what counts as done. A general statement of intent from a corporate development team has approximately zero enforcement value once the sponsor changes role.
1. Ensure a venture fund, not the corporate, leads and prices the round. 2. Cap the corporate as a minority participant on standard terms. 3. Strike any ROFR, ROFO or exclusivity language. 4. Document distribution commitments with names, quarters and definitions of done. 5. Review annually whether the relationship produced anything measurable.
Amounts, stages, dates and named participants are documented. Valuation, terms and board composition are not.
Frequently asked questions
- Is a corporate investor bad for future M&A?
- Only if they hold special rights. A minority stake with standard terms is fine; a right of first refusal or information rights over competitive plans deters other acquirers.
- What should I negotiate with a corporate investor?
- Named distribution commitments with owners and dates, standard preferred terms, no exclusivity, and no board seat at Series A.
- Where do these figures come from?
- Structured founder funding records: total raised, round stage, round amount, round date and named participants.
